论文部分内容阅读
目的:探察重症吸入性肺炎患儿采用地塞米松联合沐舒坦治疗的临床效果。方法:入选我院符合标准的新生患儿86例,按治疗方式的不同分为治疗组和对照组两组,每组各43例。比较两组患者的临床疗效、住院时间、氧疗时间、机械通气的时间等情况。结果:两组患儿治疗后病情均有改善,但治疗组的临床总有效率93.0%显著优于对照组的76.7%;治疗组患儿的住院时间、通气时间和氧疗时间明显减少,机械通气的情况也明显降低,显著优于对照组,结果具有统计学差异(P<0.05)。结论:重症吸入性肺炎的新生患儿实施沐舒坦联合地塞米松治疗,有效的改善了患儿的临床症状,安全有效,实用性强,临床效果显著,值得推广。
Objective: To investigate the clinical effect of dexamethasone and mucosolvan in children with severe aspiration pneumonia. Methods: Totally 86 neonates were enrolled in our hospital, divided into treatment group and control group according to different treatment methods, with 43 cases in each group. The clinical efficacy, hospitalization time, oxygen therapy time and the time of mechanical ventilation were compared between the two groups. Results: After treatment, both groups improved their symptoms, but the total effective rate 93.0% in the treatment group was significantly better than 76.7% in the control group. The hospitalization time, ventilation time and oxygen therapy time in the treatment group were significantly decreased. The mechanical Ventilation also significantly lower, significantly better than the control group, the results were statistically significant (P <0.05). Conclusion: The newborn infants with severe aspiration pneumonia are treated with mucosolvan and dexamethasone, which can effectively improve the clinical symptoms of children, which is safe, effective, practical, and clinically effective. It is worth to be popularized.